Genmab wisely chose not to pursue GEN3014 further, focusing instead on its existing pipeline projects. Click here to read an ...

Citigroup started coverage on shares of BioNTech (NASDAQ:BNTX – Free Report) in a report issued on Thursday morning, Marketbeat Ratings reports. The brokerage issued a buy rating and a $145.00 target ...

Analysts at HC Wainwright issued their FY2024 earnings per share (EPS) estimates for shares of BioNTech in a research report ...

Fintel reports that on March 13, 2025, Citigroup initiated coverage of BioNTech SE - Depositary Receipt () (NasdaqGS:BNTX) ...

BioNTech SE ( NASDAQ:BNTX ) just released its full-year report and things are looking bullish. Results overall ...

Deutsche Bank analyst Emmanuel Papadakis maintained a Buy rating on BioNTech SE (BNTX – Research Report) today and set a price target of ...

German biotech company BioNTech announced a financial loss of €665.3 million ($721 million) for 2024, attributing the decline ...

German biotech company BioNTech announced a loss of EURO665.3 million (USD721 million) in 2024, due to the decline of ...

The large inflow of cash from Comirnaty gross profits in 2021-22 has further secured BioNTech's financial health. Outside of BioNTech’s covid-19 vaccine candidates, we think the earliest approval ...

Operator Welcome to BioNTech's fourth quarter and full year 2024 earnings call. I would like to hand the call over to Michael ...

BioNTech (NasdaqGS:BNTX) reported a 2.49% weekly price decline following its announcement of diminished Q4 2024 earnings, where sales and net income significantly dropped compared to the previous year ...

BioNTech shares fell Monday, as the COVID-19 vaccine maker’s soft outlook offset better-than-expected quarterly results.